Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 1049-1063

  Jacob, Aishwarya G ^a   O'Brien, Dennis ^a   Singh, Ravi K ^a   Comiskey Jr , Daniel F ^a   Littleton, Robert M ^a   Mohammad, Fuad ^a   Gladman, Jordan T ^a   Widmann, Maria C ^a   Jeyaraj, Selvi C ^a   Bolinger, Cheryl ^b   Anderson, James R ^c   Barkauskas, Donald A ^d   Boris Lawrie, Kathleen ^b   Chandler, Dawn S ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ISOPROTEIN; PROTEIN MDM2; PROTEIN MDMX; RIBOSOME RNA;

ARTICLE; CANCER STAGING; CELL GROWTH; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENOTOXICITY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA SPLICING; TREATMENT OUTCOME; VALIDATION PROCESS; WESTERN BLOTTING;

ALTERNATIVE SPLICING; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; HUMANS; NUCLEAR PROTEINS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RHABDOMYOSARCOMA; STRESS, PHYSIOLOGICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84884378820     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13286     Document Type: Article

References (66)

1. Bartel F, Meye A, Würl P, Kappler M, Bache M, Lautenschlager C, Grunbaum U, Schmidt H, and Taubert H (2001). Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma. Int J Cancer 95, 168-175.
2. Sigalas I, Calvert AH, Anderson JJ, Neal DE, and Lunec J (1996). Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2, 912-917.
3. Kraus A, Neff F, Behn M, Schuermann M, Muenkel K, and Schlegel J (1999). Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. Int J Cancer 80, 930-934.
4. Sánchez-Aguilera A, Garcia JF, Sánchez-Beato M, and Piris MA (2006). Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control. Oncogene 25, 2565-2574.
5. Hori M, Shimazaki J, Inagawa S, Itabashi M, and Hori M (2000). Alternatively spliced MDM2 transcripts in human breast cancer in relation to tumor necrosis and lymph node involvement. Pathol Int 50, 786-792.
6. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, and Press MF (2001). Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61, 3212-3219.
7. Bartel F, Taylor AC, Taubert H, and Harris LC (2001). Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncol Res 12, 451-457.
8. Evdokiou A, Atkins GJ, Bouralexis S, Hay S, Raggatt LJ, Cowled PA, Graves SE, Clayer M, and Findlay DM (2001). Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone. Int J Oncol 19, 625-632.
9. Tamborini E, Della Torre G, Lavarino C, Azzarelli A, Carpinelli P, Pierotti MA, and Pilotti S (2001). Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int J Cancer 92, 790-796.
10. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, and Abe H (1998). Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 58, 609-613.
11. Chandler DS, Singh RK, Caldwell LC, Bitler JL, and Lozano G (2006). Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 66, 9502-9508.
12. alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Cancer Res 66, 9467-9473.
13. Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F, Martella C, Prodosmo A, Iacovelli S, Buttitta F, et al. (2005). Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res 65, 9687-9694.
14. Prodosmo A, Giglio S, Moretti S, Mancini F, Barbi F, Avenia N, Di Conza G, Schünemann HJ, Pistola L, Ludovini V, et al. (2008). Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med (Berl) 86, 585-596.
15. Bartel F, Schulz J, Böhnke A, Blümke K, Kappler M, Bache M, Schmidt H, Würl P, Taubert H, and Hauptmann S (2005). Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 117, 469-475.
16. Davis RJ and Barr FG (1997). Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA 94, 8047-8051.
17. Hachitanda Y, Toyoshima S, Akazawa K, and Tsuneyoshi M (1998). N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol 11, 1222-1227.
18. Minniti CP, Tsokos M, Newton WA Jr, and Helman LJ (1994). Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 101, 198-203.
19. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, et al. (2008). NF-κB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14, 369-381.
20. Xia SJ, Pressey JG, and Barr FG (2002). Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 1, 97-104.
21. Durbin AD, Somers GR, Forrester M, Pienkowska M, Hannigan GE, and Malkin D (2009). JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest 119, 1558-1570.
22. Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG, Toftgård R, and Undén AB (2006). Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J Pathol 208, 17-25.
23. Hatley ME, Tang W, Garcia MR, Finkelstein D, Millay DP, Liu N, Graff J, Galindo RL, and Olson EN (2012). A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 22, 536-546.
24. Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, Grochola LF, Bartel F, Hogendoorn PC, Wuerl P, et al. (2012). Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res 72, 4074-4084.
25. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, and Lozano G (2001). An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20, 4041-4049.
26. Lobe CG, Koop KE, Kreppner W, Lomeli H, Gertsenstein M, and Nagy A (1999). Z/AP, a double reporter for Cre-mediated recombination. Dev Biol 208, 281-292.
27. Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X, Meyhack B, Wong Staal F, and Li QX (2004). One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 36, 826-828, 830, 832-823.
28. Roberts TM and Boris-Lawrie K (2000). The 5′ RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNA. J Virol 74, 8111-8118.
29. Huang da W, Sherman BT, and Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
30. Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, and Sorensen PH (2002). Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 62, 4704-4710.
31. Rallapalli R, Strachan G, Cho B, Mercer WE, and Hall DJ (1999). A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J Biol Chem 274, 8299-8308.
32. Volk EL, Schuster K, Nemeth KM, Fan L, and Harris LC (2009). MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence. Dis Model Mech 2, 47-55.
33. Ognjanovic S, Martel G, Manivel C, Olivier M, Langer E, and Hainaut P (2012). Low prevalence of TP53 mutations and MDM2 amplifications in pediatric rhabdomyosarcoma. Sarcoma 2012, 492086.
34. Dutertre M, Sanchez G, De Cian MC, Barbier J, Dardenne E, Gratadou L, Dujardin G, Le Jossic-Corcos C, Corcos L, and Auboeuf D (2010). Cotranscriptional exon skipping in the genotoxic stress response. Nat Struct Mol Biol 17, 1358-1366.
35. Kanehisa M and Goto S (2000). KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28, 27-30.
36. Kanehisa M, Goto S, Sato Y, Furumichi M, and Tanabe M (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40, D109-D114.
37. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, and Harris LC (2000). P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 35, 96-103.
38. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, Yi SY, and Brachmann RK (2007). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 28, 289-298.
39. Fang S, Jensen JP, Ludwig RL, Vousden KH, and Weissman AM (2000). Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275, 8945-8951.
40. Honda R and Yasuda H (2000). Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476.
41. Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K, and Xiao ZX (2004). The central acidic domain of MDM2 is critical in inhibition of retinoblastomamediated suppression of E2F and cell growth. J Biol Chem 279, 53317-53322.
42. Miwa S, Uchida C, Kitagawa K, Hattori T, Oda T, Sugimura H, Yasuda H, Nakamura H, Chida K, and Kitagawa M (2006). Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner. Biochem Biophys Res Commun 340, 54-61.
43. Jones SN, Hancock AR, Vogel H, Donehower LA, and Bradley A (1998). Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA 95, 15608-15612.
44. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, and Finlay CA (1997). Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 11, 714-725.
45. McDonnell TJ, Montes de Oca Luna R, Cho S, Amelse LL, Chavez-Reyes A, and Lozano G (1999). Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol 188, 322-328.
46. Steinman HA, Burstein E, Lengner C, Gosselin J, Pihan G, Duckett CS, and Jones SN (2004). An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 279, 4877-4886.
47. Eischen CM and Boyd K (2012). Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53. PLoS One 7, e46148.
48. Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, and Lozano G (2008). Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol Cancer Res 6, 947-954.
49. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, and Lozano G (2001). Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29, 92-95.
50. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, and Marine JC (2006). Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103, 3232-3237.
51. Muñoz MJ, Pérez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S, Glover-Cutter K, Ben-Dov C, Blaustein M, Lozano JJ et al. (2009). DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 137, 708-720.
52. Mirzayans R, Andrais B, Scott A, and Murray D (2012). New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol 2012, 170325.
53. WAF1 dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations. Oncogene 17, 533-543.
54. Shay JW and Roninson IB (2004). Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933.
55. 2 arrest after DNA damage. Science 282, 1497-1501.
56. McKenna E, Traganos F, Zhao H, and Darzynkiewicz Z (2012). Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence. Cell Cycle 11, 3132-3140.
57. Jackson TR, Salmina K, Huna A, Inashkina I, Jankevics E, Riekstina U, Kalnina Z, Ivanov A, Townsend PA, Cragg MS, et al. (2012). DNA damage causes TP53dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells. Cell Cycle 12, 430-441.
58. Wade M and Wahl GM (2009). Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7, 1-11.
59. Toledo F and Wahl GM (2007). MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39, 1476-1482.
60. Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T, and Hosoi H (2009). Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 15, 4077-4084.
61. Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, Studebaker AW, Ding K, Wang S, Yang D, et al. (2009). MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer 101, 774-781.
62. Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L, and Athar M (2010). Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 70, 6566-6576.
63. Smith CW and Valcárcel J (2000). Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci 25, 381-388.
64. Barak Y, Gottlieb E, Juven-Gershon T, and Oren M (1994). Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 8, 1739-1749.
65. Singh RK, Tapia-Santos A, Bebee TW, and Chandler DS (2009). Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress. Exp Cell Res 315, 3419-3432.
66. Allende-Vega N, Dayal S, Agarwala U, Sparks A, Bourdon JC, and Saville MK (2012). p53 is activated in response to disruption of the pre-mRNA splicing machinery. Oncogene 32, 1-14.